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Abstract
Substantial anatomical and physiological changes occur during pregnancy and labour, which impact on 
drug absorption, distribution, metabolism and elimination. Reduced maternal concentrations may have a 
clinically important impact on the efficacy of anti-infectives for mother, fetus and neonate, with potential 
dosing implications. However, there is a paucity of pregnancy-specific data examining this. Existing data 
on the pharmacokinetics of anti-infectives in pregnancy are summarised and evaluated, with emphasis on 
agents that are used in treatment of HIV, TB, malaria and common bacterial infections. Limitations and 
challenges in achieving ideal study designs in pregnant populations are highlighted and key quality 
considerations for the generation of the highest quality evidence are outlined. PubMed was searched for 
each chosen anti-infective. Pharmacokinetic studies which either compared pharmacokinetics from 
pregnant women against non-pregnant controls, or which assessed concentrations against a known 
minimum inhibitory concentration were included. Two independent reviewers extracted data from each 
study and appraised them using the 24-point ClinPK Checklist. The main finding was the lack of published 
data for anti-infectives in pregnancy, despite their clinical importance. Of the studies identified, only those 
investigating cobicistat-boosted antiretroviral regimens firmly concluded that these should not be used in 
pregnancy. Most studies concluded either that further research was needed, or that there were 
significant pharmacokinetic differences between pregnant and non-pregnant participants which had 
uncertain clinical significance. Challenges in applying existing quality grading systems to these studies 
were noted, suggesting a development of a refined system for appraisal of pharmacokinetic studies in 
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Introduction 
Infections in pregnancy are common and are associated with numerous consequences for the mother, 
fetus and the neonate, including miscarriage, congenital abnormalities, fetal growth restriction, preterm 
birth and significant neonatal morbidity and mortality(1). Furthermore, the immunological changes in 
pregnancy confer a greater risk of acquiring infection, or reactivating latent infection. It is estimated that 
in some parts of Southern Africa, over 30% of pregnant women have Human Immunodeficiency Virus 
(HIV)(2). Whilst 80% of HIV-infected women worldwide are on antiretroviral treatment, there remains a 
14% mother-to-child HIV transmission rate. In 2011, there were an estimated 216,500 active tuberculosis 
cases in pregnant women globally, with increased mortality both during pregnancy and the puerperium 
(3). In 2018, 11 million pregnancies were exposed to malaria in sub-Saharan Africa, associated with higher 
risk of maternal anaemia and low birth weight(4).  Urinary tract infections (UTI) and preterm prelabour 
rupture of membranes (PPROM) with the risk of ascending infection, chorioamnionitis and maternal 
sepsis are common worldwide and pose significant risks to mother, fetus and neonate. Anti-infective 
drugs are an established part of clinical care in pregnancy, but has robust pharmacokinetic evidence 
informed the dosing schedules currently used?
During pregnancy, substantial physiological changes which impact on drug absorption, distribution, 
metabolism and elimination become evident by the second trimester (Figure 1); where severe systemic 
illness results from infection, further pharmacokinetic perturbations may occur (5)   Furthermore, 
pregnancy is a unique situation, balancing the interests of two (or more) participants. Whilst the aim of 
some anti-infectives is solely to treat the mother, others, such as antiretrovirals, must prevent vertical 
transmission, whilst also ensuring safety from adverse effects on the fetus (6). Traditionally, there has 
been reluctance to conduct drug trials in pregnant women due to the perceived risk to the fetus; dosing 
recommendations are often extrapolated from pharmacokinetic data derived from non-pregnant 
populations.  Whilst pre-clinical evaluation and assessment of potential teratogenicity and adverse fetal 
effects are centrally important, it is imperative that as far as possible, studies are undertaken in the 
population in which the drug will be used.. We believe that the pharmacokinetic data and evidence for 
dosing regimens for new and existing anti-infectives used in pregnancy should be rigorously evaluated to 
determine whether therapeutic maternal concentrations are achieved in pregnancy, or whether dose 
adjustment is required. To interpret existing data, it is necessary to understand the study objectives and 
design; whether target concentrations are known; whether the pharmacokinetic sampling schedule was 
sufficient to address the research questions; whether the pharmacometric analysis was appropriate; and 
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This review aimed firstly to summarise and evaluate existing data on the pharmacokinetics of anti-
infectives in pregnancy, focussing on agents that are commonly used worldwide. Secondly, we discuss 
some of the limitations and challenges in study design with reference to existing studies. Finally, we 
present approaches to overcome these challenges, to improve the quality of future pharmacokinetic 
studies conducted in pregnancy. 
Choice of Drugs and Methods to Synthesise Data
The following anti-infectives were chosen based on commonly-used treatment guidelines:
 Antituberculous drugs from WHO guidelines: first line: rifampicin, isoniazid, pyrazinamide, 
ethambutol; second line: moxifloxacin, linezolid, bedaquiline, delamanid
 Antimalarials from WHO guidelines: quinine (first trimester), artemether-lumefantrine (second 
and third trimester) and intravenous artesunate (severe malaria at any stage) 
 Antibiotics: benzylpenicillin administered during labour for prophylaxis against early-onset 
neonatal group B streptococcus (GBS) infection (7), erythromycin prescribed following PPROM 
(8), amoxicillin for urinary tract infection (UTI), amoxicillin/clavulanic acid, gentamicin or 
metronidazole for maternal sepsis
 Antiretrovirals: all licensed antiretroviral drugs.
The terms “pharmacokinetics” AND “pregnancy” AND “[selected drug]” were entered into PubMed for 
each chosen anti-infective, without date or language restrictions. Titles and abstracts were screened 
against the study question with evaluation of potentially relevant full text articles. Inclusion criteria were: 
1) primary pharmacokinetic study; 2) comprising pregnant women at any stage of gestation; 3) including a 
non-pregnant control group, and/or direct comparison against a known target concentration, for example 
the minimal inhibitory concentration (MIC) to be achieved in pregnant women. The non-pregnant control 
group could comprise historical controls if these data were presented and analysed within the study itself, 
versus in the discussion only. Studies in only non-pregnant participants, animal studies or those focussed 
only on placental, amniotic fluid or neonatal pharmacokinetics were excluded. 
The pharmacokinetics of antiretrovirals were recently reviewed by Hodel and colleagues. (9) From this 
comprehensive overview, studies of drugs which showed clinically significant differences in 
pharmacokinetics between pregnant and non-pregnant participants were selected for our review. Further 
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included. Similarly, a recent meta-analysis assessed artemether-lumefantrine pharmacokinetics in 
pregnant women and children(10), so only studies undertaken subsequently were included as individual 
items.
Two independent reviewers (PH and CW) extracted the following data points: population studied, control 
group, sampling occasion/s (2nd trimester/3rd trimester/intrapartum/postpartum), number of sampling 
time points, pharmacometric method, conclusion and limitations. Both reviewers also appraised each 
study and graded the quality of evidence using the ClinPK scoring system(11) (Table S1). Drug 
concentrations within cord, amniotic fluid, breastmilk and neonates/infants were beyond the scope of this 
review. Intra-partum studies were included, but women undergoing elective (pre-labour) caesarean-
section (ELCS) were classed as being participants in their third trimester, rather than in labour. Finally, all 
authors discussed the limitations of existing literature and sought to succinctly present the key design 
considerations for high quality pharmacokinetic studies in pregnancy.
Findings from review of pharmacokinetic literature
Search results are shown in Figure 2. The most frequent reason for exclusion of full text articles was lack 
of a non-pregnant comparator group. 
Table 1 summarises the included studies. Further detail regarding the study design, pharmacokinetic 
sampling schedule and results of each of these studies is provided in Table S2.  
Antituberculous drugs
Only three studies were identified, all of which involved HIV-infected pregnant women receiving first-line 
TB treatment (12-14). One of these evaluated pharmacokinetics of isoniazid, pyrazinamide and 
ethambutol and concluded that no changes were needed in dosing for pregnant women, as there were no 
significant differences between women antenatally and 7-weeks postpartum(12). However, there were 
very few paired sampling occasions where the woman acted as her own control postpartum: eight for 
isoniazid and one each for pyrazinamide and ethambutol. This relates to the four-drug intensive period of 
TB treatment being only two months long; by the postpartum sampling occasion, many women were on 
the continuation phase of treatment comprising only rifampicin and isoniazid. 
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Antimalarial drugs
The 2018 meta-analysis of artemether-lumefantrine pharmacokinetics in children and pregnant women 
concluded that day-7 plasma lumefantrine concentrations were 20% lower in pregnant women than non-
pregnant controls(10). However, despite using data from 1347 participants to generate the lumefantrine 
population pharmacokinetic model, only 40 of these were pregnant (3.12%). 
Six studies published following this meta-analysis were identified(15-20). Out of these, five were 
inconclusive regarding need for dose adjustments but rather commented that the clinical relevance of 
statistically significant differences in pharmacokinetic parameters warrants further evaluation. All the 
studies used day-7 lumefantrine concentrations of either >175ng/ml or >280ng/ml as a proxy for 
adequate dosing to avoid treatment failure, based on the demonstrated correlation between 
concentrations below these targets and risk of recrudescent malaria(16). Mosha and colleagues found 
that with the standard 3-day regimen, 9% of pregnant women had day-7 lumefantrine concentrations 
<280ng/ml, compared with 2% of non-pregnant women (17). 
Thresholds of 175 ng/ml and 280 ng/ml have both been considered (16). However, the precise 
pharmacodynamic relationship has not been elucidated and other studies have failed to demonstrate 
clear clinical correlation of subtherapeutic concentrations. Whilst further data may determine the optimal 
target, the more conservative threshold of 280 ng/ml is logical as it seems likely to reduce the risk of 
subtherapeutic effects on the parasite and reduce selection for drug-resistant parasites (16). Supporting 
this, Mosha and colleagues demonstrated that a modified regime could optimise concentrations for 
pregnant women initially below this threshold (17). Simulation from their models demonstrated that a 
modified 5-day regimen may result in only 2% of pregnant women having day-7 lumefantrine  
concentration of <280ng/ml(17). 
One study each was identified for artesunate and quinine(21, 22). Both concluded that no dose 
adjustment was needed in pregnancy, but both were limited by small sample size.  
The median ClinPK Score for the antimalarial studies was 17 (range 14-20).
Antibiotics 
Despite clinical guidelines recommending amoxicillin, benzylpenicillin, erythromycin, gentamicin and 
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29). Three studies did not use non-pregnant controls but were included as they measured concentrations 
against a target MIC(23, 24, 28). In one study, women undergoing gynaecological surgery were compared 
against women undergoing ELCS(27). There was no formal matching between these groups, but rather an 
assumption that non-pregnant women undergoing elective gynaecological surgery would provide a 
comparator to women in their third trimester undergoing ELCS. Two studies were conducted during active 
labour(23, 26). One examined use of amoxicillin for GBS colonisation in women both prior to the onset of 
labour (with PROM) and during labour(26). Eight women sampled following a dose during labour received 
an additional dose postpartum, followed by further sampling. However, this “postpartum” dose was given 
within four hours after delivery. The second labour study, by Bulska and colleagues was limited through 
use of a single sampling time point, which was immediately postpartum. 
Most studies concluded that either there were no significant differences between pregnant women and 
non-pregnant controls, or that therapeutic concentrations were achieved in pregnant women. When 
comparing gentamicin pharmacokinetics between non-pregnant women undergoing surgery and women 
undergoing ELCS, Popovic and colleagues concluded that sub-therapeutic concentrations were achieved in 
pregnancy, but drew this conclusion from samples taken at two time points subsequent to delivery(27). 
For these studies, the median ClinPK score was 15 (range 10-19).
Antiretroviral treatment
The 2019 review by Hodel  evaluated 45 clinical studies, excluding those where treatment was initiated in 
labour, and studies using non-pregnant adults as comparators(9). Therefore, all studies compared the 
same women during pregnancy and postpartum. No dose adjustments for nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and ritonavir-boosted protease 
inhibitors were recommended, as despite some significant differences in pharmacokinetics, drug 
exposures remained adequate to suppress viral replication. However, clinically significant reductions in 
cobicistat-boosted regimens mean that these are not recommended for use in pregnancy due to the risk 
of virologic failure.
We further evaluated these clinically significant studies; there are no new antiretroviral compounds with 
pregnancy-specific data. Concentrations of cobicistat and cobicistat-boosted elvitegravir and darunavir 
were significantly lower during pregnancy (30, 31). This finding was reiterated in an additional study 
published in 2020(32). Cobicistat is a potent CYP3A4 inhibitor used in combination with darunavir and 
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during pregnancy accelerates cobicistat clearance, resulting in lower concentrations of itself and the 
partner drugs.
For these studies, the median ClinPK score was 16 (range 14-17).
Study Design, Data Management, Ethical and Regulatory Considerations
We aimed to summarise and evaluate existing literature on pharmacokinetics of anti-infectives used 
during pregnancy. The limited amount of published data for these drugs, despite their clinical importance 
in pregnant women, was striking. Substantially more data exist for antiretrovirals than for antibiotics, 
antimalarial and antituberculous drugs, perhaps because a major goal of maternal treatment has been to 
prevent vertical transmission to the infant, as well as strong research partnerships and community 
advocacy compared to the other drug groups or diseases. 
Very few studies firmly concluded that drugs should not be used at the same doses as in non-pregnant 
patients, with these data relating to cobicistat-boosted antiretroviral regimens. Others, particularly 
regarding antimalarials, concluded that the significant differences between concentrations in pregnant 
and non-pregnant patients had uncertain clinical relevance. In the antibiotic category, Bulska et al found 
that maternal erythromycin concentrations were higher than the target MIC, but the limited 
transplacental transfer of the drug suggested compromised efficacy in treatment of intrauterine 
infections(23). Most stated that further research was needed to determine adequate dosing in this 
population. 
The European Medicines Agency has highlighted the need for more pharmacokinetic studies in women 
(non-pregnant, pregnant and lactating), stating that there should be an “all-encompassing approach 
regarding the inclusion and follow-up of pregnant women in well-designed clinical trials and post-
authorisation, rather than excluding them systematically”(33) . However, no legislation exists to make 
these studies mandatory and often pregnancy is a major exclusion criterion for clinical trials, with 
mandatory withdrawal should a pregnancy occur(6). Guidance from the US Food and Drug Administration 
(FDA) states that there either must be prospect of direct benefit for the woman or fetus or, if no direct 
benefit, the risk to the fetus is minimal and the knowledge cannot be obtained by any other means(34). 
Consequently, the fear of harm to the fetus from drugs often outweighs the potential benefits for the 
pregnant woman. However, in many situations, these adverse effects are only a possibility, whereas 
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It was not until 2018 that the FDA issued warnings on the use of cobicistat-containing antiretroviral 
regimens in pregnancy(6), despite them having been registered and in clinical use including in pregnancy 
for up to six years.  The median delay between registration of a new antiretroviral agent and published 
data on pharmacokinetics and safety in pregnancy is six years(6). During this interval, healthcare 
professionals face a difficult choice: prescribing a drug “off-label” with potential risks to mother and 
infant, or denying them access to a drug which could bring significant benefit.  
During labour, additional physiological changes occur, further altering the concentration-time profile of 
drugs(26). Guidance recommends use of antibiotics during labour in all pregnant women at increased risk 
of transmitting GBS to their baby during delivery. Despite the organism being carried in the genito-anal 
tract of 20-40% of UK women(35), only two studies evaluating the influence of labour on 
pharmacokinetics of anti-infectives used against GBS were identified. There are ethical and practical 
barriers to conducting these studies, but nonetheless, it is critically important to verify that adequate 
concentrations of antibiotic are reached to prevent neonatal sepsis. 
High quality pharmacokinetic studies require rigorous attention to study design and reporting. Several 
additional challenges are seen in pregnant or labouring women. For example, the physiological changes 
that occur during pregnancy take approximately six weeks after birth to resolve, therefore it is imperative 
to allow adequate time before the postpartum sampling occasion (36) ; this was a particular limitation for 
the intrapartum studies which used the immediate postpartum timepoint. Figure 3 outlines some key 
study design considerations. In this review, quality of evidence was appraised using the ClinPK Checklist, a 
list of 24 items describing the quality of design and reporting of pharmacokinetic studies. The median 
score obtained was 16, with a range of 10 to 21. Most studies were limited by small sample size and 
unmatched control populations. Those which evaluated anti-infectives which are used long-term, such as 
antiretrovirals or antituberculous drugs, could measure concentrations in the same women antepartum 
and postpartum. This comparison is more challenging to attain for drugs which are given as a short 
treatment course in late pregnancy or around delivery, unless for research purposes a repeat dose or 
treatment course is given around six weeks postpartum. In this scenario, the participant would no longer 
require the treatment for her own health and might be breastfeeding; participation in such studies would 
therefore present different risk-benefit considerations. To overcome these challenges, matched non-
pregnant women could be used as controls. 
Most studies measured total plasma concentration of drugs. However, some drugs, such as the protease 
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drug entering cells(9). In late pregnancy, decreased maternal albumin and occupation of binding sites by 
steroids and hormones may result in increased free drug fraction. If only total drug concentration is 
measured, this may be incorrectly interpreted as increased elimination. Ideally, both bound and unbound 
concentrations should be measured. 
Most identified studies employed non-compartmental analysis or population pharmacokinetic (pop-PK) 
modelling. Some studies, particularly on antimalarials, used simulation in their analysis to predict an 
adjusted dosing regimen to achieve therapeutic concentrations in pregnant women with a range of 
clinical covariates. Future clinical studies could evaluate the real-life efficacy of this simulated regimen. 
Data sharing enables data from previous clinical trials to be used in both physiologically-based 
pharmacokinetic (PBPK) and pop-PK modelling(37). However, most studies do not make their primary 
datasets available.  Increasing awareness of the need to make data Findable, Accessible, Interoperable 
and Reusable (FAIR) has not yet translated to improved access to data in studies relating to anti-infective 
exposure in pregnancy. 
Furthermore, alongside pharmacokinetic parameters, studies should ideally evaluate clinical outcomes to 
enable concentrations to be correlated with efficacy.  Sample size or study duration can make this 
challenging within the design of a pharmacokinetic study (for example end of treatment outcomes in the 
case of TB treatment). Additionally, when considering the risk-benefit ratio in the mother-infant dyad, 
other measurements such as cord: maternal blood ratios, breastmilk and infant plasma concentrations 
provide valuable information. Whilst this current review focuses on the pharmacokinetic differences 
encountered during pregnancy, these other measurements should be considered in relation to the overall 
goals of the clinical study. 
A final observation from this review is the difficulty in grading quality of evidence of pharmacokinetic 
studies. Clinical trials are frequently appraised against GRADE criteria, but many criteria are not applicable 
for pharmacokinetic studies. The Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies 
(GAPPS) system was developed for use in paediatric drug development studies(38). However, in practice, 
the allocation of greater weight to studies which used pooled datasets and simulation, irrespective of 
sample size, type of control group and number of sampling time points meant that studies that used 
paired participants antenatally and postpartum, but did not use simulation, were deemed as “weak”, 
when arguably these are higher quality. Ultimately, the ClinPK scale was considered to emphasise the key 
quality characteristics which would indicate optimal study design for a pharmacokinetic study comparing 
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system still does not fully address considerations of sample size, appropriateness of sampling schedule or 
type of control group, highlighting that there is a need for a specific grading system for studies which 
compare pharmacokinetics between populations. In conclusion, there is a paucity of high-quality research 
surrounding the pharmacokinetics of anti-infectives in pregnant women. This lack of knowledge results in 
medications being used in this population off-label, without information on efficacy. If gender equity is 
ever to be achieved in research, in addition to including pregnant women in trials of new drugs, specific 
studies to evaluate pharmacokinetics of important drugs with established, and emerging use in pregnancy 
(such as anti-infectives) must be undertaken.  Experienced women’s health trialists must collaborate with 
pharmacokinetic-pharmacodynamic and infectious disease experts to design robust studies with suitable 
controls, sample types, sampling schedules. 
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Rifampicin          
Denti 2015 HIV positive 
women with TB in 
T2 or T3 
48/48 (all 
paired) 
T3 and PP 3 Comp No dose 
adjustment needed 
21 Inaccurate timing of doses 




women with TB in 
T2 or T3 
18/8 T3 and PP 3 Comp No dose 
adjustment needed 
16 Lack of paired samples; 
Inaccurate timing of doses 
Gausi 2020 HIV positive 
women with TB in 
T2 or T3 
420/637 (210 
paired) 
T3 and PP Intensive = 6 
(32 samples) 
Sparse = 1 
(815) 
Comp Reduced levels in 
pregnancy, unclear 
clinical relevance 
18 Unclear timing of sparse 
sampling visits 




women with TB in 
T2 or T3 
13/3 (1 paired) T3 and PP 3 Comp No dose 
adjustment needed 
16 Lack of paired samples 















women with TB in 
T2 or T3 
13/3 (1 paired) T3 and PP 3 Comp No dose 
adjustment needed 




        




T2 or T3 10 NCA Further research 
needed 
20 Males in control group 




T2 or T3 1 Other Lower levels in 
pregnancy; unclear 
clinical relevance 
14 Single time point; lack of 
paired samples 




T2 or T3 4 Comp + 
simulation 
Consider modified 
5- day regimen 
19 Lack of paired samples 






T2 or T3 9 NCA Further research 
needed  
15 Lack of paired samples  




T2 or T3 24 NCA Further research 
needed  
17 Lack of paired samples 
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research needed  
Quinine         
Abdelrahim 2007 Falciparum in T2 
or T3 
8/8 (not paired) T2 or T3 7 NCA No dose 
adjustment needed 
15 Small sample size 
IV artesunate         




T2 or T3 8 NCA No dose 
adjustment needed 
 
17 Small sample size  
Antibiotics 
Amoxicillin         
Andrew 2007 Healthy, T2 or T3 16/16 (all 
paired) 
T2 and T3 
and PP 




19 Single dose of drug given  





9 IP (8 paired) 
T3/IP and 
PP 
8 Comp No dose 
adjustment needed 
14 Lack of paired samples; PP 
dose was 4 hours after 
labour 
Benzylpenicillin         
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Erythromycin         
Bulska 2015 GBS positive, ELCS 
or VD 
34/8(IP)/42 PP 1 Other Concentration>MIC 
achieved in 
maternal serum, 
not in umbilical 
vein serum 
15 Single time point; unclear 
analysis  
Larsen 1998 T2 or T3 with C 
trachomatis 






10 No controls; unclear 
analysis; inter-individual 
variability not shown 
Gentamicin          








2 Comp Concentration<MIC 
achieved 
15 Lack of paired samples; both 
time-points PP   
Metronidazole         
Wang 2010 T1, T2 or T3 20/0 T1, T2 or 
T3 
10 Comp No dose 
adjustment needed 
17 No controls – compared to 
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Table 1. Key data points extracted from included pharmacokinetic studies 
Comp = compartmental analysis; ELCS = elective C section; GBS = group B streptococcus; IP = intra-partum (during labour); MIC = minimum inhibitory concentration; NCA = 
non-compartmental analysis; PP = post-partum; PROM = premature rupture of membranes; T2 = second trimester; T3 = third trimester; VD = vaginal delivery.  
T3 and PP in pregnancy  not standardised  
Bukkems 2020 HIV positive T3 14/12 (paired) T3 and PP 9 NCA Should not be used 
in pregnancy 
14 Small sample size 
Darunavir-
Cobicistat 
        
Crauwels 2018 HIV positive T2 6/6 (paired) T2 and T3 
and PP 
8 NCA Should not be used 
in pregnancy 






































 Artemether-Lumefantrine (n=30) 
Quinine (n=33) 
IV Artesunate (n=8) 
Amoxicillin (n=23) 









 Artemether-Lumefantrine (n=20) 
Quinine (n=27) 











 Artemether-Lumefantrine (n=10) 
Quinine (n=6) 






Full text articles considered 
Rifampicin (n=4 [3 reviews, 1 animal]) 
Isoniazid (n=1 [infant]) 
Pyrazinamide (n=0) 
Ethambutol (n=1 [review]) 
 Artemether-Lumefantrine (n=4 [no controls]) 
Quinine (n=5 [no controls]) 
IV Artesunate (n=1 [review]) 
Amoxicillin (n=4 [no controls]) 
Benzylpenicillin (n=1, [not pharmacokinetic]) 
Erythromycin (n=5 [2 no controls, 3 animal]) 
Gentamicin (n=4 [no controls]) 
Metronidazole (n=1 [no controls]) 





 Artemether-Lumefantrine (n=6) 
Quinine (n=1) 



































*Antiretroviral data primarily drawn from
existing review (Hodel et al.) and therefore
not detailed in our search strategy
cpt_2192_f3.pdf
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